Clinical trial
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic…
NCT00169156 · Lymphoma Study Association, Other · Completed
Key facts
| NCT number | NCT00169156 |
|---|---|
| Title | A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma |
| Official title | Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Untreated T-cell Angioimmunoblastic Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Prednisone, Doxorubicine, Cyclophosphamide, Vincristine |
| Enrollment | 27 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Nov 1, 2012 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 13, 2017 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: